Nuveen LLC Acquires Shares of 306,386 AxoGen, Inc. $AXGN

Nuveen LLC acquired a new stake in AxoGen, Inc. (NASDAQ:AXGN) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 306,386 shares of the medical equipment provider’s stock, valued at approximately $5,668,000. Nuveen LLC owned 0.67% of AxoGen at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the company. Divisadero Street Capital Management LP boosted its stake in shares of AxoGen by 2.7% in the fourth quarter. Divisadero Street Capital Management LP now owns 26,972 shares of the medical equipment provider’s stock worth $444,000 after acquiring an additional 700 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of AxoGen by 4.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,128 shares of the medical equipment provider’s stock worth $398,000 after acquiring an additional 926 shares during the last quarter. State of Wyoming acquired a new stake in shares of AxoGen in the fourth quarter worth approximately $31,000. Rhumbline Advisers boosted its stake in shares of AxoGen by 3.5% in the first quarter. Rhumbline Advisers now owns 60,264 shares of the medical equipment provider’s stock worth $1,115,000 after acquiring an additional 2,032 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its stake in shares of AxoGen by 9.8% in the fourth quarter. MetLife Investment Management LLC now owns 26,034 shares of the medical equipment provider’s stock worth $429,000 after acquiring an additional 2,319 shares during the last quarter. 80.29% of the stock is owned by institutional investors and hedge funds.

AxoGen Stock Down 9.0%

Shares of NASDAQ:AXGN opened at $14.79 on Tuesday. The company has a quick ratio of 2.67, a current ratio of 4.14 and a debt-to-equity ratio of 0.59. The business has a fifty day moving average of $12.49 and a two-hundred day moving average of $14.42. The stock has a market cap of $680.49 million, a P/E ratio of -147.89 and a beta of 1.00. AxoGen, Inc. has a 52-week low of $9.22 and a 52-week high of $21.00.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AXGN. Wall Street Zen raised AxoGen from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Canaccord Genuity Group lowered their price target on AxoGen from $26.00 to $24.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $26.00.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.